Pharvaris CEO sells 2,292 shares at $29.22

Pharvaris N.V.’s Chief Executive Officer, Berndt Modig, sold 2,292 shares of common stock in an open-market transaction.

Rhea-AI Filing Summary

Pharvaris N.V.’s Chief Executive Officer, Berndt Modig, sold 2,292 shares of common stock in an open-market transaction. The sale on May 18, 2026 was executed at a weighted average price of $29.222 per share under a Rule 10b5-1 trading plan.

Following this transaction, Modig directly holds 137,500 shares of Pharvaris common stock. The footnote explains that the sold shares include stock previously acquired upon vesting of restricted stock units, and that individual sale prices ranged from $29.47 to $30.40.

Insider Trade Summary 10b5-1

Net Seller: 2,292 shares

Net Sell 1 txn

Insider Modig Berndt

Role Chief Executive Officer

Sold 2,292 shs ($67K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,292	$29.222	$67K

Holdings After Transaction: Common Stock — 137,500 shares (Direct)

Footnotes (1)

1. F1. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $29.47 - $30.40. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 2,292 shares Weighted average sale price: $29.222 per share Price range of sales: $29.47–$30.40 per share +1 more

4 metrics

Shares sold 2,292 shares Open-market sale on May 18, 2026

Weighted average sale price $29.222 per share Common stock sale on May 18, 2026

Price range of sales $29.47–$30.40 per share Individual trade prices within reported transaction

Shares held after transaction 137,500 shares CEO’s direct common stock holdings post-sale

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, open-market sale

4 terms

Rule 10b5-1 trading plan financial

"transactions on the reported date pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"include shares of common stock acquired upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The reported price represents a weighted average sale price"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pharvaris (PHVS) report for CEO Berndt Modig?

Pharvaris reported that CEO Berndt Modig sold 2,292 shares of common stock. The open-market sale occurred on May 18, 2026, at a weighted average price of $29.222 per share, executed pursuant to a pre-established Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares does the CEO hold after this sale?

After the reported transaction, CEO Berndt Modig directly holds 137,500 Pharvaris common shares. This figure reflects his position following the May 18, 2026 open-market sale of 2,292 shares executed under a Rule 10b5-1 trading plan, as disclosed in the Form 4.

At what prices were the Pharvaris (PHVS) CEO’s shares sold in this Form 4?

The CEO’s sale used a weighted average price of $29.222 per share. According to the footnote, individual sale prices in the May 18, 2026 transactions ranged from $29.47 to $30.40, all executed pursuant to a Rule 10b5-1 trading plan.

Was the Pharvaris (PHVS) CEO’s share sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transactions were completed under a Rule 10b5-1 trading plan. Such pre-arranged plans schedule trades in advance, indicating the timing of the May 18, 2026 sale was determined before the actual trading date.

Do the Pharvaris (PHVS) CEO’s sold shares include vested restricted stock units?

Yes. The filing notes that the reported shares include common stock acquired upon vesting of restricted stock units on various dates. Those vested shares were then sold in the May 18, 2026 open-market transactions disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 05:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Modig Berndt

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		S		2,292	D	$29.222(1)	137,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $29.47 - $30.40. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Marnus Nel, Attorney-in-Fact for Berndt Modig	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)